GeneralBullishBlockonomi · 3h ago5/10
📰
AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment
Bernstein has reaffirmed an outperform rating on AstraZeneca (AZN), identifying its non-oncology portfolio as significantly undervalued with 37% upside potential to a £186 price target. The stock gained 3.1% on the analyst note, suggesting market recognition of hidden value in overlooked business segments.